<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39335569</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>The Importance of the Concentration of Selected Cytokines (IL-6, IL-10, IL-12, IL-15, TNF-α) and Inflammatory Markers (CRP, NLR, PLR, LMR, SII) in Predicting the Course of Rehabilitation for Patients after COVID-19 Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2055</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12092055</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">In the course of COVID-19, there may be an excessive immune response of the body with the release of large amounts of pro-inflammatory cytokines, causing a "cytokine storm", also known as cytokine release syndrome (CRS). The COVID-19 pandemic has shown how important an integrated approach to health care is, with physiotherapy being one of its fundamental aspects. The aim of this study was to analyze the potential relationship between the level of selected cytokines (IL-6, IL-10, IL-12, IL-15, TNF-α) and inflammatory markers (CRP, NLR, PLR, LMR, SII) and the duration of rehabilitation in patients after COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The examined patients participated in a comprehensive rehabilitation program, which included breathing exercises, aerobic training, and strength and endurance training. Peripheral venous blood samples were also collected from each patient.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Factors such as gender, smoking status, IL-10, and the presence of pneumonia during infection were significantly associated with the length of rehabilitation after COVID-19.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The course of rehabilitation after COVID-19 may depend on many factors, including smoking, the presence of pneumonia due to infection, and some parameters of inflammation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mińko</LastName><ForeName>Alicja</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2299-3958</Identifier><AffiliationInfo><Affiliation>Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, 71-210 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turoń-Skrzypińska</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, 71-210 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rył</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5954-4489</Identifier><AffiliationInfo><Affiliation>Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, 71-210 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mańkowska</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Laboratory Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cymbaluk-Płoska</LastName><ForeName>Aneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Reconstructive Surgery and Gynecological Oncology, Pomeranian Medical University, 70-111 Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotter</LastName><ForeName>Iwona</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-4337-6476</Identifier><AffiliationInfo><Affiliation>Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, 71-210 Szczecin, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FSN-321-06/23</GrantID><Agency>Pomeranian Medical University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cytokine</Keyword><Keyword MajorTopicYN="N">rehabilitation</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39335569</ArticleId><ArticleId IdType="pmc">PMC11429050</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12092055</ArticleId><ArticleId IdType="pii">biomedicines12092055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asser P.A.L., Soundararajan K. The vital role of physiotherapy during COVID-19: A systematic review. Work. 2021;70:687–694. doi: 10.3233/WOR-210450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/WOR-210450</ArticleId><ArticleId IdType="pubmed">34719461</ArticleId></ArticleIdList></Reference><Reference><Citation>Filgueira T.O., Castoldi A., Santos L.E.R., de Amorim G.J., de Sousa Fernandes M.S., Anastácio W.d.L.D.N., Campos E.Z., Santos T.M., Souto F.O. The Relevance of a Physical Active Lifestyle and Physical Fitness on Immune Defense: Mitigating Disease Burden, With Focus on COVID-19 Consequences. Front. Immunol. 2021;12:587146. doi: 10.3389/fimmu.2021.587146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.587146</ArticleId><ArticleId IdType="pmc">PMC7892446</ArticleId><ArticleId IdType="pubmed">33613573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Jiang M., Chen X., Montaner L.J. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J. Leukoc. Biol. 2020;108:17–41. doi: 10.1002/JLB.3COVR0520-272R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3COVR0520-272R</ArticleId><ArticleId IdType="pmc">PMC7323250</ArticleId><ArticleId IdType="pubmed">32534467</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Ma Q., Li C., Liu R., Zhao L., Wang W., Zhang P., Liu X., Gao G., Liu F., et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg. Microbes Infect. 2020;9:1123–1130. doi: 10.1080/22221751.2020.1770129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Qin L., Zhang P., Li K., Liang L., Sun J., Xu B., Dai Y., Li X., Zhang C., et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. J. Clin. Investig. 2020;5:e139834. doi: 10.1172/jci.insight.139834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.139834</ArticleId><ArticleId IdType="pmc">PMC7406242</ArticleId><ArticleId IdType="pubmed">32501293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanza C., Romenskaya T., Manetti A.C., Franceschi F., La Russa R., Bertozzi G., Maiese A., Savioli G., Volonnino G., Longhitano Y. Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina. 2022;58:144. doi: 10.3390/medicina58020144.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina58020144</ArticleId><ArticleId IdType="pmc">PMC8876409</ArticleId><ArticleId IdType="pubmed">35208467</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z., Cai T., Fan L., Lou K., Hua X., Huang Z., Gao G. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int. J. Infect. Dis. 2020;95:332–339. doi: 10.1016/j.ijid.2020.04.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.04.041</ArticleId><ArticleId IdType="pmc">PMC7195003</ArticleId><ArticleId IdType="pubmed">32334118</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D.M., Kim-Schulze S., Huang H.-H., Beckmann N.D., Nirenberg S., Wang B., Lavin Y., Swartz T.H., Madduri D., Stock A., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020;26:1636–1643. doi: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi A., Shobeiri P., Kulasinghe A., Rezaei N. Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis. Front. Immunol. 2021;12:741061. doi: 10.3389/fimmu.2021.741061.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.741061</ArticleId><ArticleId IdType="pmc">PMC8569430</ArticleId><ArticleId IdType="pubmed">34745112</ArticleId></ArticleIdList></Reference><Reference><Citation>Velazquez S., Madurga R., Castellano J.M., Rodriguez-Pascual J., de Aguiar Diaz Obregon S.R., Jimeno S., Montero J.I., Wichner P.S.V., López-Escobar A. Hemogram-Derived Ratios as Prognostic Markers of ICU Admission in COVID-19. BMC Emerg. Med. 2021;21:89. doi: 10.1186/s12873-021-00480-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12873-021-00480-w</ArticleId><ArticleId IdType="pmc">PMC8314257</ArticleId><ArticleId IdType="pubmed">34315437</ArticleId></ArticleIdList></Reference><Reference><Citation>Simadibrata D.M., Pandhita B.A.W., Ananta M.E., Tango T. Platelet-to-Lymphocyte Ratio, a Novel Biomarker to Predict the Severity of COVID-19 Patients: A Systematic Review and Meta-Analysis. J. Intensive Care Soc. 2022;23:20–26. doi: 10.1177/1751143720969587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1751143720969587</ArticleId><ArticleId IdType="pmc">PMC7649648</ArticleId><ArticleId IdType="pubmed">38603090</ArticleId></ArticleIdList></Reference><Reference><Citation>Copaescu A., Smibert O., Gibson A., Phillips E.J., Trubiano J.A. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. J. Allergy Clin. Immunol. 2020;146:518–534.e1. doi: 10.1016/j.jaci.2020.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7471766</ArticleId><ArticleId IdType="pubmed">32896310</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz V.J., Illescas-Montes R., Puerta-Puerta J.M., Ruiz C., Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62–75. doi: 10.1016/j.cytogfr.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar S.K., Damodar S., Gujar S., Das M. IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: Results from meta-analysis and regression. Heliyon. 2021;7:e06155. doi: 10.1016/j.heliyon.2021.e06155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e06155</ArticleId><ArticleId IdType="pmc">PMC7846230</ArticleId><ArticleId IdType="pubmed">33553782</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang W., Rutz S., Crellin N.K., Valdez P.A., Hymowitz S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 2011;29:71–109. doi: 10.1146/annurev-immunol-031210-101312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101312</ArticleId><ArticleId IdType="pubmed">21166540</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi P., Behzadi E., Ranjbar R. IL-12 Family Cytokines: General Characteristics, Pathogenic Microorganisms, Receptors, and Signalling Pathways. Acta Microbiol. Immunol. Hung. 2016;63:1–25. doi: 10.1556/030.63.2016.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1556/030.63.2016.1.1</ArticleId><ArticleId IdType="pubmed">27020866</ArticleId></ArticleIdList></Reference><Reference><Citation>Leite M.d.M., Gonzalez-Galarza F.F., da Silva B.C.C., Middleton D., dos Santos E.J.M. Predictive immunogenetic markers in COVID-19. Hum. Immunol. 2021;82:247–254. doi: 10.1016/j.humimm.2021.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2021.01.008</ArticleId><ArticleId IdType="pmc">PMC7817393</ArticleId><ArticleId IdType="pubmed">33546902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandikattu H.K., Venkateshaiah S.U., Kumar S., Mishra A. IL-15 immunotherapy is a viable strategy for COVID-19. Cytokine Growth Factor Rev. 2020;54:24–31. doi: 10.1016/j.cytogfr.2020.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.008</ArticleId><ArticleId IdType="pmc">PMC7537239</ArticleId><ArticleId IdType="pubmed">32536564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Tang J., Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J. Med. Virol. 2020;92:441–447. doi: 10.1002/jmv.25689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25689</ArticleId><ArticleId IdType="pmc">PMC7167192</ArticleId><ArticleId IdType="pubmed">31994742</ArticleId></ArticleIdList></Reference><Reference><Citation>Iskandar A., Mayashinta D.K., Robert R., Samsu N., Endharti A.T., Widjajanto E. Correlation Between IL-8, C-Reactive Proteins (CRP) and Neutrophil to Lymphocyte Ratio (NLR) as Predictor of Mortality in COVID-19 Patients with Diabetes Mellitus Comorbidity. Int. J. Gen. Med. 2023;16:2349–2354. doi: 10.2147/IJGM.S412070.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S412070</ArticleId><ArticleId IdType="pmc">PMC10259590</ArticleId><ArticleId IdType="pubmed">37313045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A.S., Rout A. Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19. J. Clin. Med. Res. 2020;12:448–453. doi: 10.14740/jocmr4240.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr4240</ArticleId><ArticleId IdType="pmc">PMC7331861</ArticleId><ArticleId IdType="pubmed">32655740</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Liu C., Mao Z., Xiao M., Wang L., Qi S., Zhou F. Predictive Values of Neutrophil-to-Lymphocyte Ratio on Disease Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Crit. Care. 2020;24:647. doi: 10.1186/s13054-020-03374-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03374-8</ArticleId><ArticleId IdType="pmc">PMC7667659</ArticleId><ArticleId IdType="pubmed">33198786</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindra R., Ramamurthy P., Aslam S.M., Kulkarni A.K.S., Ramamurthy P.S. Platelet Indices and Platelet to Lymphocyte Ratio (PLR) as Markers for Predicting COVID-19 Infection Severity. Cureus. 2022;14:e28206. doi: 10.7759/cureus.28206.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.28206</ArticleId><ArticleId IdType="pmc">PMC9484704</ArticleId><ArticleId IdType="pubmed">36158356</ArticleId></ArticleIdList></Reference><Reference><Citation>Dymicka-Piekarska V., Dorf J., Milewska A., Łukaszyk M., Kosidło J.W., Kamińska J., Wolszczak-Biedrzycka B., Naumnik W. Neutrophil/Lymphocyte Ratio (NLR) and Lymphocyte/Monocyte Ratio (LMR)—Risk of Death Inflammatory Biomarkers in Patients with COVID-19. J. Inflamm. Res. 2023;16:2209–2222. doi: 10.2147/JIR.S409871.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S409871</ArticleId><ArticleId IdType="pmc">PMC10224725</ArticleId><ArticleId IdType="pubmed">37250103</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivieri F., Sabbatinelli J., Bonfigli A.R., Sarzani R., Giordano P., Cherubini A., Antonicelli R., Rosati Y., Del Prete S., Di Rosa M., et al. Routine Laboratory Parameters, Including Complete Blood Count, Predict COVID-19 in-Hospital Mortality in Geriatric Patients. Mech. Ageing Dev. 2022;204:111674. doi: 10.1016/j.mad.2022.111674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2022.111674</ArticleId><ArticleId IdType="pmc">PMC8996472</ArticleId><ArticleId IdType="pubmed">35421418</ArticleId></ArticleIdList></Reference><Reference><Citation>Righetti R.F., Onoue M.A., Politi F.V.A., Teixeira D.T., de Souza P.N., Kondo C.S., Moderno E.V., Moraes I.G., Maida A.L.V., Pastore L., et al. Physiotherapy Care of Patients with Coronavirus Disease 2019 (COVID-19)—A Brazilian Experience. Clinics. 2020;75:e2017. doi: 10.6061/clinics/2020/e2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2020/e2017</ArticleId><ArticleId IdType="pmc">PMC7297520</ArticleId><ArticleId IdType="pubmed">32578825</ArticleId></ArticleIdList></Reference><Reference><Citation>Order of the President of the National Health Fund No. 172/2021/DSOZ of 18 October 2021.  [(accessed on 9 March 2023)]; Available online:  https://baw.nfz.gov.pl/NFZ/tabBrowser/mainPage.</Citation></Reference><Reference><Citation>Klok F.A., Boon G.J., Barco S., Endres M., Geelhoed J.M., Knauss S., Rezek S.A., Spruit M.A., Vehreschild J., Siegerink B. The Post-COVID-19 Functional Status scale: A tool to measure functional status over time after COVID-19. Eur. Respir. J. 2020;56:2001494. doi: 10.1183/13993003.01494-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01494-2020</ArticleId><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Paternostro-Sluga T., Grim-Stieger M., Posch M., Schuhfried O., Vacariu G., Mittermaier C., Bittner C., Fialka-Moser V. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J. Rehabil. Med. 2008;40:665–671. doi: 10.2340/16501977-0235.</Citation><ArticleIdList><ArticleId IdType="doi">10.2340/16501977-0235</ArticleId><ArticleId IdType="pubmed">19020701</ArticleId></ArticleIdList></Reference><Reference><Citation>Minakata Y., Hayata A., Matsunaga K., Nakanishi M., Yamamoto N. Differences in physical activity according to mMRC grade in patients with COPD. Int. J. Chronic Obstr. Pulm. Dis. 2016;11:2203–2208. doi: 10.2147/COPD.S109694.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S109694</ArticleId><ArticleId IdType="pmc">PMC5028078</ArticleId><ArticleId IdType="pubmed">27695306</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham B.L., Steenbruggen I., Miller M.R., Barjaktarevic I.Z., Cooper B.G., Hall G.L., Hallstrand T.S., Kaminsky D.A., McCarthy K., McCormack M.C., et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am. J. Respir. Crit. Care Med. 2019;200:e70–e88. doi: 10.1164/rccm.201908-1590ST.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201908-1590ST</ArticleId><ArticleId IdType="pmc">PMC6794117</ArticleId><ArticleId IdType="pubmed">31613151</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S.J., Puhan M.A., Andrianopoulos V., Hernandes N.A., Mitchell K.E., Hill C.J., Lee A.L., Camillo C.A., Troosters T., Spruit M.A., et al. An official systematic review of the European Respiratory Society/American Thoracic Society: Measurement properties of field walking tests in chronic respiratory disease. Eur. Respir. J. 2014;44:1447–1478. doi: 10.1183/09031936.00150414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00150414</ArticleId><ArticleId IdType="pubmed">25359356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandaliya H., Jones M., Oldmeadow C., Nordman I.I.C. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI) Transl. Lung Cancer Res. 2019;8:886–894. doi: 10.21037/tlcr.2019.11.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tlcr.2019.11.16</ArticleId><ArticleId IdType="pmc">PMC6976360</ArticleId><ArticleId IdType="pubmed">32010567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R.-H., Wen W.-X., Jiang Z.-P., Du Z.-P., Ma Z.-H., Lu A.-L., Li H.-P., Yuan F., Wu S.-B., Guo J.-W., et al. The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage. Front. Immunol. 2023;14:1115031. doi: 10.3389/fimmu.2023.1115031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1115031</ArticleId><ArticleId IdType="pmc">PMC9969881</ArticleId><ArticleId IdType="pubmed">36860868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali A.M., Rostam H.M., Fatah M.H., Noori C.M., Ali K.M., Tawfeeq H.M. Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients. Immun. Inflamm. Dis. 2022;10:e582. doi: 10.1002/iid3.582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.582</ArticleId><ArticleId IdType="pmc">PMC8926504</ArticleId><ArticleId IdType="pubmed">34939346</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi Y., Ge Y., Wu B., Zhang W., Wu T., Wen T., Liu J., Guo X., Huang C., Jiao Y., et al. Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China. J. Infect. Dis. 2020;222:746–754. doi: 10.1093/infdis/jiaa363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa363</ArticleId><ArticleId IdType="pmc">PMC7337752</ArticleId><ArticleId IdType="pubmed">32563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia F., Wang G., Xu J., Long J., Deng F., Jiang W. Role of tumor necrosis factor-α in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia. Aging. 2021;13:23895–23912. doi: 10.18632/aging.203663.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203663</ArticleId><ArticleId IdType="pmc">PMC8610114</ArticleId><ArticleId IdType="pubmed">34725309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kgatle M.M., Lawal I.O., Mashabela G., Boshomane T.M.G., Koatale P.C., Mahasha P.W., Ndlovu H., Vorster M., Rodrigues H.G., Zeevaart J.R., et al. COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks. Front. Immunol. 2021;12:752380. doi: 10.3389/fimmu.2021.752380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.752380</ArticleId><ArticleId IdType="pmc">PMC8531724</ArticleId><ArticleId IdType="pubmed">34691068</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y., Li M., Chang M., Liu R., Qiu J., Wang K., Deng C., Shen Y., Zhu J., Wang W., et al. Inflammation: Roles in Skeletal Muscle Atrophy. Antioxidants. 2022;11:1686. doi: 10.3390/antiox11091686.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox11091686</ArticleId><ArticleId IdType="pmc">PMC9495679</ArticleId><ArticleId IdType="pubmed">36139760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W., Xu T., Wang Y., Wu C., Wang L., Yang X., Sun H. The role of inflammatory factors in skeletal muscle injury. Biotarget. 2018;2:7. doi: 10.21037/biotarget.2018.04.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/biotarget.2018.04.01</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahlavani H.A. Exercise Therapy for People with Sarcopenic Obesity: Myokines and Adipokines as Effective Actors. Front. Endocrinol. 2022;13:811751. doi: 10.3389/fendo.2022.811751.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.811751</ArticleId><ArticleId IdType="pmc">PMC8892203</ArticleId><ArticleId IdType="pubmed">35250869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirayder U., Inal-Ince D., Kepenek-Varol B., Acik C. Long-Term Characteristics of Severe COVID-19: Respiratory Function, Functional Capacity, and Quality of Life. Int. J. Environ. Res. Public Health. 2022;19:6304. doi: 10.3390/ijerph19106304.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19106304</ArticleId><ArticleId IdType="pmc">PMC9141122</ArticleId><ArticleId IdType="pubmed">35627841</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Xie J., Fiskesund R., Dong W., Liang X., Lv J., Jin X., Liu J., Mo S., Zhang T., et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat. Commun. 2018;9:873. doi: 10.1038/s41467-018-03225-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03225-9</ArticleId><ArticleId IdType="pmc">PMC5830447</ArticleId><ArticleId IdType="pubmed">29491374</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua R.L., Lukassen S., Trump S., Hennig B.P., Wendisch D., Pott F., Debnath O., Thürmann L., Kurth F., Völker M.T., et al. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. Nat. Biotechnol. 2020;38:970–979. doi: 10.1038/s41587-020-0602-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0602-4</ArticleId><ArticleId IdType="pubmed">32591762</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisen W.H., Wohleb E.S., Jaime-Ramirez A.C., Bolyard C., Yoo J.Y., Russell L., Hardcastle J., Dubin S., Muili K., Yu J., et al. The Impact of Macrophage- and Mi-croglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clin. Cancer Res. 2015;21:3274–3285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780415</ArticleId><ArticleId IdType="pubmed">25829396</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv J., Wang Z., Qu Y., Zhu H., Zhu Q., Tong W., Bao L., Lv Q., Cong J., Li D., et al. Distinct uptake, amplification, and release of SARS-CoV-2 by M1 and M2 alveolar macrophages. Cell Discov. 2021;7:24. doi: 10.1038/s41421-021-00258-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00258-1</ArticleId><ArticleId IdType="pmc">PMC8043100</ArticleId><ArticleId IdType="pubmed">33850112</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>